| abstract |
The present invention relates to novel N- (4-carbamimidoylphenyl) glycine derivatives of formula (I) wherein R1 is alkyl; R2 is hydrogen, hydroxyalkoxy, alkoxycarbonyloxyalkoxy or haloalkoxycarbonyloxyalkoxy; R3 is hydrogen, alkoxy or heterocycloalkoxy; R4 is hydrogen or a residue of an ester which can be cleaved under physiological conditions; , alkynyloxycarbonyl, 5-methyl-2-oxo [1,3] dioxol-4-ylmethoxycarbonyl, arylcarbonyloxy, alkylaminocarbonyloxy, arylaminocarbonyloxy, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl or arylaminocarbonyl; , chlorine or bromine) and their hydrates or solvates and / or physiologically acceptable salts and / or physiologically acceptable esters thereof ing; with the proviso that the following compounds are not included in the formula (I): (RS) - (4-Carbamimidoylphenylamino) - (3,5-diethoxy-2-fluorophenyl) -acetic acid ethyl ester; (RS) - (4-carbamimidoyl-phenylamino) - (3,5-diethoxy-2-fluorophenyl) acetic acid; (RS) - (4-carbamimidoyl-phenylamino) - (2-fluoro-3,5-dimethoxyphenyl) acetic acid; and (RS) - (4-Carbamimidoyl-phenylamino) - (2-fluoro-3,5-dimethoxyphenyl) -acetic acid ethyl ester, and their hydrates or solvates and pharmaceutically acceptable esters and / or pharmaceutically acceptable esters thereof. SHE |